Relay Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	15.36	10.01	25.55	1.38	3.03
Revenue Growth (YoY)	53.44%	-60.83%	1749.82%	-54.41%	-96.34%
Cost of Revenue	259.51	315.44	326.39	243.01	169.39
Gross Profit	-244.15	-305.43	-300.84	-241.62	-166.36
Selling, General & Admin	58.59	80.24	78.58	69.33	59.75
Operating Expenses	58.59	80.24	78.58	69.33	59.75
Operating Income	-302.74	-385.67	-379.42	-310.95	-226.11
Interest & Investment Income	27.04	34.75	31.05	8.79	0.83
Other Non Operating Income (Expenses)	-0.78	0.01	-0.02	-0.02	-0
EBT Excluding Unusual Items	-276.48	-350.91	-348.4	-302.19	-225.28
Merger & Restructuring Charges	-	-	-	-	-0.9
Gain (Loss) on Sale of Investments	-	-	-	-	-11.86
Other Unusual Items	-	13.21	6.42	11.68	-2.84
Pretax Income	-276.48	-337.71	-341.97	-290.51	-363.87
Net Income	-276.48	-337.71	-341.97	-290.51	-363.87
Net Income to Common	-276.48	-337.71	-341.97	-290.51	-363.87
Shares Outstanding (Basic)	172	143	123	112	95
Shares Outstanding (Diluted)	172	143	123	112	95
Shares Change (YoY)	20.10%	16.55%	9.21%	17.97%	123.22%
EPS (Basic)	-1.61	-2.36	-2.79	-2.59	-3.82
EPS (Diluted)	-1.61	-2.36	-2.79	-2.59	-3.82
Free Cash Flow	-235.87	-251.13	-304.44	-238.55	-77.88
Free Cash Flow Per Share	-1.38	-1.76	-2.48	-2.13	-0.82
Operating Margin	-1971.59%	-3854.04%	-1485.25%	-22516.44%	-7464.74%
Profit Margin	-1800.58%	-3374.72%	-1338.66%	-21036.13%	-12012.94%
Free Cash Flow Margin	-1536.08%	-2509.49%	-1191.74%	-17273.86%	-2571.05%
EBITDA	-299.18	-380.21	-374.15	-306.82	-222.18
D&A For EBITDA	3.56	5.46	5.27	4.13	3.93
EBIT	-302.74	-385.67	-379.42	-310.95	-226.11
Revenue as Reported	15.36	10.01	25.55	1.38	3.03

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q